These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 12431211)

  • 1. Authors' reply: first-phase parameters in hepatitis C viral kinetics.
    Layden JE; Neumann AU; Layden TJ
    J Viral Hepat; 2002 Nov; 9(6):466. PubMed ID: 12431211
    [No Abstract]   [Full Text] [Related]  

  • 2. First-phase parameters in hepatitis C viral kinetics.
    Zeuzem S; Herrmann E
    J Viral Hepat; 2002 Sep; 9(5):332-3. PubMed ID: 12225326
    [No Abstract]   [Full Text] [Related]  

  • 3. Hepatitis C kinetics: mathematical modeling of viral response to therapy.
    Layden TJ; Mika B; Wiley TE
    Semin Liver Dis; 2000; 20(2):173-83. PubMed ID: 10946422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline.
    Layden JE; Layden TJ; Reddy KR; Levy-Drummer RS; Poulakos J; Neumann AU
    J Viral Hepat; 2002 Sep; 9(5):340-5. PubMed ID: 12225328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current and future applications of viral clearance kinetics in the treatment of hepatitis C].
    Buti M
    Gastroenterol Hepatol; 2004 Feb; 27 Suppl 1():24-9. PubMed ID: 15195531
    [No Abstract]   [Full Text] [Related]  

  • 6. Viral kinetics in hepatitis C.
    Lutchman G; Hoofnagle JH
    Hepatology; 2003 Jun; 37(6):1257-9. PubMed ID: 12774002
    [No Abstract]   [Full Text] [Related]  

  • 7. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
    Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors.
    Akuta N; Suzuki F; Tsubota A; Suzuki Y; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Hepatol; 2002 Dec; 37(6):831-6. PubMed ID: 12445425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis and management of hepatitis C virus-infected children.
    Jhaveri R
    Pediatr Infect Dis J; 2011 Nov; 30(11):983-5. PubMed ID: 21997662
    [No Abstract]   [Full Text] [Related]  

  • 10. Mathematical modeling of HCV infection and treatment.
    Dahari H; Shudo E; Ribeiro RM; Perelson AS
    Methods Mol Biol; 2009; 510():439-53. PubMed ID: 19009281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infection fighters. Hepatitis C--is a cure possible?
    TreatmentUpdate; 2005; 17(1):8-9. PubMed ID: 17225319
    [No Abstract]   [Full Text] [Related]  

  • 12. Viral kinetics and treatment response in patients with hepatitis C during induction and standard interferon therapy in combination with ribavirin.
    Carlsson T; Weiland O; Reichard O
    Scand J Gastroenterol; 2002 Oct; 37(10):1228-34. PubMed ID: 12408530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of relapse following treatment for hepatitis C: is whole blood more than the sum of its parts?
    Shire N; Koziel MJ
    Clin Infect Dis; 2004 Dec; 39(12):1761-3. PubMed ID: 15578396
    [No Abstract]   [Full Text] [Related]  

  • 14. Novel interferons for treatment of hepatitis C virus.
    Clark V; Nelson DR
    Clin Liver Dis; 2009 Aug; 13(3):351-63. PubMed ID: 19628153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Significance of zinc in hepatitis C].
    Takagi H; Takizawa D; Yuasa K; Suzuki H; Naganuma A; Nagamine T
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():663-7. PubMed ID: 26846018
    [No Abstract]   [Full Text] [Related]  

  • 16. Does iron reduction improve sustained viral responses to interferon monotherapy in hepatitis C patients? Maybe, but is this the right question?
    Shedlofsky SI
    Am J Gastroenterol; 2002 May; 97(5):1093-6. PubMed ID: 12014712
    [No Abstract]   [Full Text] [Related]  

  • 17. Mechanism of interferon resistance in hepatitis C.
    Gretch D
    Lancet; 2001 Nov; 358(9294):1662-4. PubMed ID: 11728538
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of hepatitis C: a decision that needs careful consideration.
    Wright TL
    Am J Med; 1999 Aug; 107(2):180-1. PubMed ID: 10460052
    [No Abstract]   [Full Text] [Related]  

  • 19. HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients.
    Salmon D; Bani-Sadr F; Gilbert C; Rosenthal E; Valantin MA; Simon A; Neau D; Morlat P; Loko MA; Wittkop L; Dabis F;
    J Clin Virol; 2015 Dec; 73():32-35. PubMed ID: 26528903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in carboxy-terminal part of E2 including PKR/eIF2alpha phosphorylation homology domain and interferon sensitivity determining region of nonstructural 5A of hepatitis C virus 1b: their correlation with response to interferon monotherapy and viral load.
    Ukai K; Ishigami M; Yoshioka K; Kawabe N; Katano Y; Hayashi K; Honda T; Yano M; Goto H
    World J Gastroenterol; 2006 Jun; 12(23):3722-8. PubMed ID: 16773689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.